Archives

  • 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • br Conflict of interest br Acknowledgments Part of this

    2019-07-11


    Conflict of interest
    Acknowledgments Part of this work was supported by Institut Francais en Egypte, and the Academy of Scientific Research and Technology in Egypt under the frame of “Imhotep Project N°: 31681XL” and “STDF/IFE project N° 30630″
    Introduction NSAIDs play an important role in the management of inflammatory diseases [24]. For several years, researchers have tried to identify safer and more effective types of anti-inflammatory drugs. The β-d-mannuronic D-Mannitol what (M2000) molecule (Fig. 1) is a new agent with the lowest molecular weight and no toxicity compared with other NSAIDs [25]. This fact could be observed in the published paper indicating the anti-aging effect of this drug in an animal model [26]. In addition, The TUNEL assay results also demonstrated that M2000 can induce apoptosis with no toxicity. The induction of apoptosis together with MMP inhibition could be indicative of a chemopreventive mechanism of M2000 [27]. The potent pharmacological effect of M2000 on microRNA-146a, interleukin-1 receptor-associated kinase 1 (IRAK1), tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) as targets for the reduction of inflammatory reactions was examined [28]. Our data showed that the M2000 is a novel designed drug which could be classified as a NSAID, with the immunosuppressive property [[25], [29], [30]].
    Material and methods
    Results
    Discussion
    Funding